Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

Clinical factors associated with cutaneous histopathologic findings in dermatomyositis.

Wolstencroft PW, Rieger KE, Leatham HW, Fiorentino DF.

J Cutan Pathol. 2019 Jun;46(6):401-410. doi: 10.1111/cup.13442. Epub 2019 Apr 3.

PMID:
30737826
2.

Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis.

Wolstencroft PW, Casciola-Rosen L, Fiorentino DF.

JAMA Dermatol. 2018 Oct 1;154(10):1199-1203. doi: 10.1001/jamadermatol.2018.2549.

PMID:
30140893
3.

Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis.

Tartar DM, Chung L, Fiorentino DF.

Clin Dermatol. 2018 Jul - Aug;36(4):508-524. doi: 10.1016/j.clindermatol.2018.04.008. Epub 2018 Apr 12. Review.

PMID:
30047434
4.

Dermatomyositis Clinical and Pathological Phenotypes Associated with Myositis-Specific Autoantibodies.

Wolstencroft PW, Fiorentino DF.

Curr Rheumatol Rep. 2018 Apr 10;20(5):28. doi: 10.1007/s11926-018-0733-5. Review.

PMID:
29637414
5.

Factors Associated With Clinical Remission of Skin Disease in Dermatomyositis.

Wolstencroft PW, Chung L, Li S, Casciola-Rosen L, Fiorentino DF.

JAMA Dermatol. 2018 Jan 1;154(1):44-51. doi: 10.1001/jamadermatol.2017.3758. Erratum in: JAMA Dermatol. 2018 Jan 1;154(1):116.

6.

Cutaneous and Systemic Findings Associated With Nuclear Matrix Protein 2 Antibodies in Adult Dermatomyositis Patients.

Rogers A, Chung L, Li S, Casciola-Rosen L, Fiorentino DF.

Arthritis Care Res (Hoboken). 2017 Dec;69(12):1909-1914. doi: 10.1002/acr.23210. Epub 2017 Nov 2.

7.

Pillars Article: IL-10 Inhibits Cytokine Production by Activated Macrophages. J. Immunol. 1991. 147: 3815-3822.

Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A.

J Immunol. 2016 Sep 1;197(5):1539-46. No abstract available.

8.

Pillars Article: IL-10 Acts on the Antigen-presenting Cell to Inhibit Cytokine Production by Thl Cells. J. Immunol. 1991. 146: 3444-3451.

Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A.

J Immunol. 2016 Sep 1;197(5):1531-8. No abstract available.

9.

Ovoid Palatal Patch in Dermatomyositis: A Novel Finding Associated With Anti-TIF1γ (p155) Antibodies.

Bernet LL, Lewis MA, Rieger KE, Casciola-Rosen L, Fiorentino DF.

JAMA Dermatol. 2016 Sep 1;152(9):1049-51. doi: 10.1001/jamadermatol.2016.1429. No abstract available.

10.

Characterization of patients with clinical overlap of morphea and systemic sclerosis: A case series.

Chen JK, Chung L, Fiorentino DF.

J Am Acad Dermatol. 2016 Jun;74(6):1272-4. doi: 10.1016/j.jaad.2015.12.051. No abstract available.

PMID:
27185438
11.

Leukotriene B4 Activates Pulmonary Artery Adventitial Fibroblasts in Pulmonary Hypertension.

Qian J, Tian W, Jiang X, Tamosiuniene R, Sung YK, Shuffle EM, Tu AB, Valenzuela A, Jiang S, Zamanian RT, Fiorentino DF, Voelkel NF, Peters-Golden M, Stenmark KR, Chung L, Rabinovitch M, Nicolls MR.

Hypertension. 2015 Dec;66(6):1227-1239. doi: 10.1161/HYPERTENSIONAHA.115.06370. Epub 2015 Oct 5.

12.

PUF60: a prominent new target of the autoimmune response in dermatomyositis and Sjögren's syndrome.

Fiorentino DF, Presby M, Baer AN, Petri M, Rieger KE, Soloski M, Rosen A, Mammen AL, Christopher-Stine L, Casciola-Rosen L.

Ann Rheum Dis. 2016 Jun;75(6):1145-51. doi: 10.1136/annrheumdis-2015-207509. Epub 2015 Aug 7.

13.

Validation of the Cutaneous Dermatomyositis Disease Area and Severity Index: characterizing disease severity and assessing responsiveness to clinical change.

Anyanwu CO, Fiorentino DF, Chung L, Dzuong C, Wang Y, Okawa J, Carr K, Propert KJ, Werth VP.

Br J Dermatol. 2015 Oct;173(4):969-74. doi: 10.1111/bjd.13915. Epub 2015 Aug 11.

14.

Risk of Serious Infection With Biologic and Systemic Treatment of Psoriasis: Results From the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Kalb RE, Fiorentino DF, Lebwohl MG, Toole J, Poulin Y, Cohen AD, Goyal K, Fakharzadeh S, Calabro S, Chevrier M, Langholff W, You Y, Leonardi CL.

JAMA Dermatol. 2015 Sep;151(9):961-9. doi: 10.1001/jamadermatol.2015.0718.

PMID:
25970800
15.

Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis.

Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L.

J Am Acad Dermatol. 2015 Mar;72(3):449-55. doi: 10.1016/j.jaad.2014.12.009. Epub 2015 Jan 14.

16.

Surgical treatment of systemic sclerosis--is it justified to offer peripheral sympathectomy earlier in the disease process?

Momeni A, Sorice SC, Valenzuela A, Fiorentino DF, Chung L, Chang J.

Microsurgery. 2015 Sep;35(6):441-6. doi: 10.1002/micr.22379. Epub 2015 Jan 14.

PMID:
25585522
17.

Amyopathic dermatomyositis: definitions, diagnosis, and management.

Bailey EE, Fiorentino DF.

Curr Rheumatol Rep. 2014 Dec;16(12):465. doi: 10.1007/s11926-014-0465-0. Review.

PMID:
25366932
18.

Cutaneous ulceration in dermatomyositis: association with anti-melanoma differentiation-associated gene 5 antibodies and interstitial lung disease.

Narang NS, Casciola-Rosen L, Li S, Chung L, Fiorentino DF.

Arthritis Care Res (Hoboken). 2015 May;67(5):667-72. doi: 10.1002/acr.22498.

19.

Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.

Fiorentino DF, Chung LS, Christopher-Stine L, Zaba L, Li S, Mammen AL, Rosen A, Casciola-Rosen L.

Arthritis Rheum. 2013 Nov;65(11):2954-62. doi: 10.1002/art.38093.

20.

Molecular profiling to diagnose a case of atypical dermatomyositis.

Sarin KY, Chung L, Kim J, Higgs BW, Jallal B, Yao Y, Fiorentino DF.

J Invest Dermatol. 2013 Dec;133(12):2796-2799. doi: 10.1038/jid.2013.240. Epub 2013 Jun 3. No abstract available.

21.

Localized cutaneous fibrosing disorders.

Yaqub A, Chung L, Rieger KE, Fiorentino DF.

Rheum Dis Clin North Am. 2013 May;39(2):347-64. doi: 10.1016/j.rdc.2013.02.013. Epub 2013 Mar 16. Review.

PMID:
23597968
22.

Clinical presentation and evaluation of dermatomyositis.

Marvi U, Chung L, Fiorentino DF.

Indian J Dermatol. 2012 Sep;57(5):375-81. doi: 10.4103/0019-5154.100486.

23.

Pillars article: homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science. 1990. 248: 1230-1234.

Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR.

J Immunol. 2012 Sep 1;189(5):2072-6. No abstract available.

24.

Skin disease in dermatomyositis.

Zaba LC, Fiorentino DF.

Curr Opin Rheumatol. 2012 Nov;24(6):597-601. Review.

PMID:
22907594
25.

Identification of activated cytokine pathways in the blood of systemic lupus erythematosus, myositis, rheumatoid arthritis, and scleroderma patients.

Higgs BW, Zhu W, Richman L, Fiorentino DF, Greenberg SA, Jallal B, Yao Y.

Int J Rheum Dis. 2012 Feb;15(1):25-35. doi: 10.1111/j.1756-185X.2011.01654.x. Epub 2011 Aug 31.

PMID:
22324944
26.

Consensus guidelines for the management of plaque psoriasis.

Hsu S, Papp KA, Lebwohl MG, Bagel J, Blauvelt A, Duffin KC, Crowley J, Eichenfield LF, Feldman SR, Fiorentino DF, Gelfand JM, Gottlieb AB, Jacobsen C, Kalb RE, Kavanaugh A, Korman NJ, Krueger GG, Michelon MA, Morison W, Ritchlin CT, Stein Gold L, Stone SP, Strober BE, Van Voorhees AS, Weiss SC, Wanat K, Bebo BF Jr; National Psoriasis Foundation Medical Board.

Arch Dermatol. 2012 Jan;148(1):95-102. doi: 10.1001/archdermatol.2011.1410.

PMID:
22250239
27.

Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis.

Arefiev K, Fiorentino DF, Chung L.

Int J Rheumatol. 2011;2011:201787. doi: 10.1155/2011/201787. Epub 2011 Oct 27.

28.

Pathogenesis of dermatomyositis: role of cytokines and interferon.

Kao L, Chung L, Fiorentino DF.

Curr Rheumatol Rep. 2011 Jun;13(3):225-32. doi: 10.1007/s11926-011-0166-x. Review.

PMID:
21318338
29.

A pilot study of etanercept treatment for pemphigus vulgaris.

Fiorentino DF, Garcia MS, Rehmus W, Kimball AB.

Arch Dermatol. 2011 Jan;147(1):117-8. doi: 10.1001/archdermatol.2010.409. No abstract available.

PMID:
21242406
30.

The direct cellular target of topically applied pimecrolimus may not be infiltrating lymphocytes.

Fiorentino DF, Chen RO, Stewart DB, Brown KK, Sundram UN.

Br J Dermatol. 2011 May;164(5):996-1003. doi: 10.1111/j.1365-2133.2010.10190.x. Epub 2011 Apr 12.

PMID:
21166661
31.

Tyrosine kinases in inflammatory dermatologic disease.

Paniagua RT, Fiorentino DF, Chung L, Robinson WH.

J Am Acad Dermatol. 2011 Aug;65(2):389-403. doi: 10.1016/j.jaad.2010.04.026. Epub 2010 Jun 26. Review.

32.

Molecular framework for response to imatinib mesylate in systemic sclerosis.

Chung L, Fiorentino DF, Benbarak MJ, Adler AS, Mariano MM, Paniagua RT, Milano A, Connolly MK, Ratiner BD, Wiskocil RL, Whitfield ML, Chang HY, Robinson WH.

Arthritis Rheum. 2009 Feb;60(2):584-91. doi: 10.1002/art.24221.

33.

Type I interferon in the induction or exacerbation of dermatomyositis: what this observation tells us about the naturally occurring disease.

Fiorentino DF.

Arch Dermatol. 2008 Oct;144(10):1379-82. doi: 10.1001/archderm.144.10.1379. No abstract available.

PMID:
18936404
34.

Capillary regeneration in scleroderma: stem cell therapy reverses phenotype?

Fleming JN, Nash RA, McLeod DO, Fiorentino DF, Shulman HM, Connolly MK, Molitor JA, Henstorf G, Lafyatis R, Pritchard DK, Adams LD, Furst DE, Schwartz SM.

PLoS One. 2008 Jan 16;3(1):e1452. doi: 10.1371/journal.pone.0001452. Erratum in: PLoS ONE. 2008;3(8). doi: 10.1371/annotation/6b021f46-17bd-4ffe-a378-a1b8d24a1398.

35.

A pilot trial of rituximab in the treatment of patients with dermatomyositis.

Chung L, Genovese MC, Fiorentino DF.

Arch Dermatol. 2007 Jun;143(6):763-7.

PMID:
17576943
36.

The Yin and Yang of TNF-{alpha} inhibition.

Fiorentino DF.

Arch Dermatol. 2007 Feb;143(2):233-6. No abstract available.

PMID:
17310003
37.

Update on cutaneous vasculitis.

Grzeszkiewicz TM, Fiorentino DF.

Semin Cutan Med Surg. 2006 Dec;25(4):221-5. Review.

PMID:
17174842
38.

Successful use of rituximab for cutaneous vasculitis.

Chung L, Funke AA, Chakravarty EF, Callen JP, Fiorentino DF.

Arch Dermatol. 2006 Nov;142(11):1407-10. No abstract available.

PMID:
17116830
39.

Muir-Torre syndrome: confirmation of diagnosis by immunohistochemical analysis of cutaneous lesions.

Fiorentino DF, Nguyen JC, Egbert BM, Swetter SM.

J Am Acad Dermatol. 2004 Mar;50(3):476-8. No abstract available.

PMID:
14988697
40.

Cutaneous vasculitis.

Fiorentino DF.

J Am Acad Dermatol. 2003 Mar;48(3):311-40. Review.

PMID:
12637912
41.
42.

Molecular analysis of the interaction of calcineurin with drug-immunophilin complexes.

Clipstone NA, Fiorentino DF, Crabtree GR.

J Biol Chem. 1994 Oct 21;269(42):26431-7.

43.

Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase.

Kuo CJ, Chung J, Fiorentino DF, Flanagan WM, Blenis J, Crabtree GR.

Nature. 1992 Jul 2;358(6381):70-3.

PMID:
1614535
44.

IL-10 inhibits cytokine production by activated macrophages.

Fiorentino DF, Zlotnik A, Mosmann TR, Howard M, O'Garra A.

J Immunol. 1991 Dec 1;147(11):3815-22.

PMID:
1940369
45.

Diversity of cytokine synthesis and function of mouse CD4+ T cells.

Mosmann TR, Schumacher JH, Street NF, Budd R, O'Garra A, Fong TA, Bond MW, Moore KW, Sher A, Fiorentino DF.

Immunol Rev. 1991 Oct;123:209-29. Review. No abstract available.

PMID:
1684780
46.

IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells.

Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, O'Garra A.

J Immunol. 1991 May 15;146(10):3444-51.

PMID:
1827484
47.

Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI.

Vieira P, de Waal-Malefyt R, Dang MN, Johnson KE, Kastelein R, Fiorentino DF, deVries JE, Roncarolo MG, Mosmann TR, Moore KW.

Proc Natl Acad Sci U S A. 1991 Feb 15;88(4):1172-6.

48.

Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF1.

Hsu DH, de Waal Malefyt R, Fiorentino DF, Dang MN, Vieira P, de Vries J, Spits H, Mosmann TR, Moore KW.

Science. 1990 Nov 9;250(4982):830-2.

PMID:
2173142
49.
50.

Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI.

Moore KW, Vieira P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR.

Science. 1990 Jun 8;248(4960):1230-4. Erratum in: Science 1990 Oct 26;250(4980):494.

PMID:
2161559

Supplemental Content

Loading ...
Support Center